RecruitingNot ApplicableNCT06998745

The Impact of MTM Model on the Efficacy and Safety of Anticoagulant Therapy in Postoperative Colorectal Cancer Patients

Sponsor

Sixth Affiliated Hospital, Sun Yat-sen University

Enrollment

327 participants

Start Date

May 1, 2025

Study Type

INTERVENTIONAL

Conditions

Thrombosis, Venous

Summary

Anticoagulants are classified as high-risk medications, with their main adverse drug events (ADEs) being recurrent venous thromboembolism (VTE) and bleeding events.Postoperative colorectal cancer (CRC) patients exhibit a high probability of recurrent VTE and bleeding during anticoagulation therapy.The Medication Therapy Management (MTM) model will contribute to reducing ADEs associated with anticoagulants in CRC patients.

Eligibility

Min Age: 18 YearsMax Age: 100 Years

Inclusion Criteria2

Patients with histologically confirmed CRC and symptomatic or incidental VTE who received anticoagulant treatment.
CRC patients with VTE treated with an anticoagulant for at least 3 moths.

Interventions

BEHAVIORALMedication Therapy Management (MTM) model

MTM model comprising five core elements: Medication Therapy Review (MTR), Personal Medication Record (PMR), Medication-Related Action Plan (MAP), interventions \& referrals, and documentation \& follow-up

Locations(1)

Sixth Affiliated Hospital, Sun Yat-sen University

Guangzhou, Guangdong, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06998745